BioGaia has signed three new exclusive agreements for Prodentis, with Hansamed Ltd for sales in Canada, with BioCulture for sales in the Philippines and with MTC Pharma Co Ltd for sales in Vietnam. All three distribution partners will sell Prodentis under the BioGaia brand and plan to launch during 2017.
BioGaia’s oral health products contain the patented and well-studied probiotic Lactobacillus reuteri Prodentis, which in close to 30 clinical studies has shown positive effects on above all gingivitis and periodontal disease.
The portfolio consists of lozenges and chewing gum for consumers and oil drops for professional use. Today BioGaia's oral health products are sold in more than 20 countries worldwide and the strategy is to continue to expand this global network. As the market for probiotics in oral health is growing, BioGaia see a large potential for Prodentis within the coming years.
Most of BioGaia’s partners selling Prodentis focus on medical marketing, and this will also be the business model in the three new countries.
”We have a very strong focus on developing our oral health business and our sales of Prodentis, for which we have strong clinical evidence. I am therefore very happy that we have signed another three agreements with solid partners in both Canada and Asia”, says Axel Sjöblad, Managing Director, BioGaia.
Latest press releases from BioGaia
2017-04-04 Notice to attend the Annual General Meeting of BioGaia AB (publ)
2017-03-16 BioGaia signs exclusive agreement in Australia
2017-02-10 BioGaia Year-end report 2016